A third COVID-19 vaccine could enter the fight against the new virus in the coming days. But what does its safety profile look like?
While a panel of independent experts discussed the vaccine’s approval Friday, Food and Drug Administration staff released documents earlier this week finding that the jab has a favorable safety profile without identifying specific problems with the release of the vaccine. an EUA would hinder. ‘
In the information documents, no COVID-19-related deaths were detected in the vaccinated experimental group on 5 February, indicating that the vaccine reduces COVID-19-related deaths. There were seven deaths associated with the coronavirus in the placebo group.
HOW DO WE KNOW COVID-19 BOSSEINTE SAFE?
The most common reactions associated with the vaccine included injection site pain, headache, fatigue and myalgia, which were mostly ‘mild and moderate’, resolving within two days of vaccination. Participants aged 18-59 had more frequent reactions than those over 60.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
“No specific safety concerns were identified in subgroup analyzes by age, race, ethnicity, medical comorbidities or previous SARS-CoV-2 infection, according to the documents. The committee notes five cases of urticaria, or red swelling, among vaccinated participants. The committee said that this non-serious event was “possibly related to the vaccine.” Furthermore, insufficient data behind blood clots and tinnitus could not determine a “causal link between these events and the vaccine”. .